Sarepta Therapeutics (NASDAQ:SRPT) Earns Buy Rating from Analysts at Jefferies Financial Group

Jefferies Financial Group began coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report published on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $165.00 target price on the biotechnology company’s stock.

SRPT has been the subject of a number of other reports. Cantor Fitzgerald reiterated a “neutral” rating and set a $152.00 target price on shares of Sarepta Therapeutics in a research note on Friday, September 20th. UBS Group upped their price objective on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Citigroup reduced their price target on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Finally, Barclays dropped their price objective on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $182.95.

Sarepta Therapeutics Price Performance

NASDAQ SRPT opened at $132.02 on Monday. Sarepta Therapeutics has a one year low of $55.25 and a one year high of $173.25. The stock has a 50-day moving average of $128.78 and a 200 day moving average of $132.40. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90. The company has a market capitalization of $12.48 billion, a price-to-earnings ratio of 1,200.18 and a beta of 0.82.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. During the same quarter last year, the firm posted ($0.27) EPS. The business’s quarterly revenue was up 38.9% compared to the same quarter last year. On average, sell-side analysts forecast that Sarepta Therapeutics will post 1.45 EPS for the current year.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Michael Andrew Chambers bought 37,038 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were bought at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the purchase, the director now owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Michael Andrew Chambers bought 37,038 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the transaction, the director now owns 284,034 shares in the company, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently made changes to their positions in SRPT. Mather Group LLC. purchased a new position in Sarepta Therapeutics during the 1st quarter valued at approximately $28,000. Riggs Asset Managment Co. Inc. grew its holdings in shares of Sarepta Therapeutics by 125.0% in the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 125 shares in the last quarter. Innealta Capital LLC purchased a new position in shares of Sarepta Therapeutics in the second quarter valued at $31,000. New Covenant Trust Company N.A. bought a new stake in Sarepta Therapeutics in the first quarter worth $32,000. Finally, GAMMA Investing LLC raised its stake in Sarepta Therapeutics by 37.0% during the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 87 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.